RECRUITING

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Talk to us

Conditions

Lymphoma, B-CellLymphomaLarge-cell LymphomaLarge B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaMediastinal B-Cell Diffuse Large Cell Lymphomaoncologisthemotologic oncologistlarge cell lymphomaDLBCLDiffuse Large B Cell LymphomaHematolo-GIST23-164Memorial Sloan Kettering Cancer Center

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Official Title

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers

Quick Facts

Study Start:2023-07-03
Study Completion:2028-07-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05940272

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Currently a hemotologic oncologist providing care to patients with DLBCL
  2. * Per medical record, is being treated by a hematologic oncologist participating in this study
  3. * Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
  4. * Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or autologous stem cell transplant (ASCT)
  5. * Self-identify as Black and/or White
  6. * Per medical record, 18 years of age or older
  7. * Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
  8. 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  9. 2. What is your preferred language for healthcare? (must respond English)
  1. * Per self-report, planning to leave the cancer center in the next 12 months
  2. * Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
  3. * Per research staff judgment and/or self-report, too ill or weak to complete study procedures
  4. * Per medical record or self-report, receiving hospice care at the time of enrollment

Contacts and Locations

Study Contact

Kelly McConnell, PhD
CONTACT
646-888-0026
McConneK@mskcc.org
Revecca Saracino, PhD
CONTACT
646-888-0263
jamesr@mskcc.org

Principal Investigator

Kelly McConnell, PhD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York, 10065
United States
NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)
New York, New York, 10065
United States
Weill Cornell Medical College (Data analysis only)
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Kelly McConnell, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-03
Study Completion Date2028-07-03

Study Record Updates

Study Start Date2023-07-03
Study Completion Date2028-07-03

Terms related to this study

Keywords Provided by Researchers

  • oncologist
  • hemotologic oncologist
  • lymphoma
  • large cell lymphoma
  • large b-cell lymphoma
  • DLBCL
  • Diffuse Large B Cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma
  • Hematolo-GIST
  • 23-164
  • Memorial Sloan Kettering Cancer Center

Additional Relevant MeSH Terms

  • Lymphoma, B-Cell
  • Lymphoma
  • Large-cell Lymphoma
  • Large B-cell Lymphoma
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma